Advertisement

Phosphodiesterase Inhibitor Ameliorates Asthma, COPD in Early Trials — Physician’s First Watch

Medical News |
October 25, 2013

Phosphodiesterase Inhibitor Ameliorates Asthma, COPD in Early Trials

By Joe Elia

An inhaled dual phosphodiesterase inhibitor, RPL554, shows promise against asthma and chronic obstructive pulmonary disease in a series of preliminary studies in the Lancet Respiratory Medicine. Inhibiting phosphodiesterases 3 and 4 would, in theory, both increase bronchodilation and control inflammation.

The studies, each including less than 35 subjects, were conducted by the drug developer. They ranged from safety studies in healthy people to studies of bronchodilation and inflammatory control in patients with asthma or COPD.

Generally, RPL554 produced rapid bronchodilation in both conditions and also had an anti-inflammatory effect, as measured by neutrophil counts in sputum after challenge. The drug had a good safety profile, but the courses of therapy were brief — none lasting more than a week.

A commentator urges careful studies of RPL554's cardiovascular effects. She concludes that the drug "could be one of the most substantial advances for some time" in managing these conditions.

Reader Comments (2)

THEODORE STREHAN Physician, Geriatrics

Sounds promising. We do need another agent or two to decrease dependence on steroids.cMyself included.

r. Patrick Malone MB, BCh, MRCGP Physician, Family Medicine/General Practice, Sneem, Co. Kerry, Ireland

Excellent source of information

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement